Two Cardiovascular Trial Hits Get Merck & Co.’s Blood Pumping
Sotatercept And MK-0616 Both Blockbuster-Tipped
Executive Summary
Merck has taken two important steps towards its goal of achieving eight new cardiovascular drug approvals by 2030, presenting promising data for two potential blockbusters at the ACC meeting.
You may also be interested in...
Merck & Co.’s Big Ambition To ‘Democratize’ PCSK9s
Phase III studies testing the oral PCSK9 inhibitor MK-0616 for high cholesterol will begin in the second half of the year and include a broad program enrolling primary and secondary prevention patients.
Merck & Co.’s Big Ambition To ‘Democratize’ PCSK9s
Phase III studies testing the oral PCSK9 inhibitor MK-0616 for high cholesterol will begin in the second half of the year and include a broad program enrolling primary and secondary prevention patients.
Buy-And-Bill A Bust For Novartis's Leqvio?
The US commercial strategy for the PCSK9 inhibitor Leqvio was tied to reimbursement under Medicare Part B, but it hasn't developed the way Novartis envisioned.